Tirzepatide vs. Semaglutide: Comparing GLP-1 Weight Loss Medications

If you’re researching medical weight loss in 2026, you’ve almost certainly encountered two names: semaglutide and tirzepatide. Both are injectable medications that have produced remarkable weight loss results in clinical trials, but they’re not identical. Understanding the differences can help you have a more informed conversation with your provider about which option is best for you.

The mechanism: single vs. dual agonist

This is the core difference. Semaglutide is a GLP-1 receptor agonist—it activates one receptor system. Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates two receptor systems simultaneously: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide).

Both GLP-1 and GIP are incretin hormones released after eating, but they act through somewhat different pathways. GIP appears to enhance the effects of GLP-1 on appetite and metabolism while also having direct effects on fat tissue. The dual action is thought to explain tirzepatide’s slightly greater efficacy in head-to-head comparisons.

Clinical trial results compared

In the SURMOUNT-1 trial, tirzepatide at its highest dose (15 mg) produced an average weight loss of 22.5% over 72 weeks. By comparison, semaglutide 2.4 mg in the STEP 1 trial produced 14.9% weight loss over 68 weeks.

However, direct comparison across different trials has limitations—patient populations, study designs, and endpoints can differ. The SURPASS-2 trial did directly compare tirzepatide to semaglutide 1.0 mg (a lower dose than used for weight management) in type 2 diabetes patients, and tirzepatide showed superior A1C reduction and weight loss at all doses tested.

Both medications produce clinically meaningful results that far exceed what’s achievable with lifestyle changes alone for most patients.

Side effect profiles

Both medications share similar gastrointestinal side effects: nausea, vomiting, diarrhea, and constipation. These are most common during dose titration and tend to improve over time.

Some providers observe anecdotally that tirzepatide may cause somewhat less nausea than semaglutide at comparable efficacy levels, possibly because the GIP component modulates gastrointestinal effects differently. However, individual experiences vary widely, and neither medication can be declared categorically “easier to tolerate.”

Cost and access

Brand-name pricing for both medications is significant—roughly $1,000–$1,600 per month without insurance. Insurance coverage varies widely depending on your plan and diagnosis.

Compounded versions of both semaglutide and tirzepatide are available through 503B pharmacies at substantially lower cost, making treatment accessible to patients who might otherwise be priced out. Availability and pricing of compounded formulations can change, so discuss current options with your provider.

Which should you choose?

There’s no universal answer. Tirzepatide may produce slightly greater weight loss on average, but semaglutide has a longer track record and more extensive cardiovascular outcome data (the SELECT trial). Some patients who don’t respond well to one medication do better on the other.

Your provider can help determine which is most appropriate based on your medical history, weight loss goals, insurance coverage, and tolerance profile. The good news is that both are excellent options backed by strong clinical evidence.